These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19115932)

  • 1. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
    Yu Y; Pilgrim P; Zhou W; Gagliano N; Frezza EE; Jenkins M; Weidanz JA; Lustgarten J; Cannon M; Bumm K; Cobos E; Kast WM; Chiriva-Internati M
    Viral Immunol; 2008 Dec; 21(4):435-42. PubMed ID: 19115932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells.
    Yu Y; Pilgrim P; Yan J; Zhou W; Jenkins M; Gagliano N; Bumm K; Cannon M; Milzani A; Dalle-Donne I; Kast WM; Cobos E; Chiriva-Internati M
    J Transl Med; 2008 Oct; 6():56. PubMed ID: 18834548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
    Liu Y; Chiriva-Internati M; You C; Luo R; You H; Prasad CK; Grizzi F; Cobos E; Klimberg VS; Kay H; Mehta JL; Hermonat PL
    Cancer Gene Ther; 2005 Mar; 12(3):304-12. PubMed ID: 15565181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
    Chiriva-Internati M; Liu Y; Weidanz JA; Grizzi F; You H; Zhou W; Bumm K; Barlogie B; Mehta JL; Hermonat PL
    Blood; 2003 Nov; 102(9):3100-7. PubMed ID: 12855576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
    Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
    J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
    Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [rAAV/BA46-transfected dendritic cells can induce specific cellular immunity].
    You CX; Su J; Liao WJ; Zhang JY; Liu Y; Paul LH; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2146-9. PubMed ID: 19114342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
    Liu Y; Chiriva-Internati M; Grizzi F; Salati E; Roman JJ; Lim S; Hermonat PL
    Cancer Gene Ther; 2001 Dec; 8(12):948-57. PubMed ID: 11781657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in immune function of dendritic cells infected by recombinant adenovirus containing Her2/neu gene of extracellular and transmembrane domain proteins].
    Ma SD; Luo RC; Ding ZH; Lu F; Yuan CQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1184-7. PubMed ID: 16939917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
    Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
    Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of the cytotoxic T lymphocyte response against hepatocellular carcinoma by transduction of cancer cells with an adeno-associated virus carrying the interferon-γ gene.
    Zhou J; Ma P; Li J; Cui X; Song W
    Mol Med Rep; 2016 Apr; 13(4):3197-205. PubMed ID: 26936017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo.
    Wang P; Munger CM; Joshi AD; Pirruccello SJ; Joshi SS
    Breast Cancer Res Treat; 2004 Jan; 83(1):15-23. PubMed ID: 14997051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.